- - Could Eli Lilly Turn Today's GLP‑1 Obesity Boom Into Multi‑Decade, Millionaire‑Maker Gains?

Adria Cimino, The Motley FoolFebruary 10, 2026 at 2:10 AM

0

Key Points -

Demand for weight loss drugs is high, and analysts predict the market may reach nearly $100 billion in a few years.

Eli Lilly dominates the GLP-1 market in the U.S.

10 stocks we like better than Eli Lilly ›

Eli Lilly (NYSE: LLY) has already scored major accomplishments in the GLP-1 boom. The company has delivered double-digit revenue growth, taken leadership in the market, and seen its stock price explode higher. GLP-1 drugs have been in great demand as they've helped people quickly and safely shed pounds.

Now, though, after Lilly stock's 200% increase over three years, you may be wondering if the growth story has fully played out or if there's more to come. Could this pharma giant turn today's GLP-1 obesity drug boom into multi-decade, millionaire-maker gains? Let's find out.

Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »

An investor smiles while looking at something on a phone.

Image source: Getty Images.

How GLP-1 drugs work

First, let's take a quick look at these popular treatments. GLP-1 drugs act on hormones involved in the digestion process, helping manage blood sugar levels and appetite. Today, with the exception of Novo Nordisk's recently released weight loss pill, GLP-1 drugs are taken in an injectable format.

Novo Nordisk makes semaglutide, commercialized as Ozempic for type 2 diabetes and as Wegovy for weight loss. And Lilly makes tirzepatide, sold as Mounjaro for the former indication and Zepbound for the latter. Doctors, however, have been known to also prescribe Ozempic and Mounjaro off-label for patients aiming to lose weight. Novo recently won approval for Wegovy in pill form, and Lilly's oral weight loss candidate, orforglipron, currently is under regulatory review.

Novo was first to the GLP-1 market, but in recent years, Lilly has chipped away at its market share. Today, Lilly is the leader with more than 60% of the U.S. market. And Lilly's revenue has steadily climbed thanks to its strengths in the GLP-1 space. In the recent quarter, for example, Mounjaro and Zepbound each delivered triple-digit revenue gains and together brought in more than $11 billion.

Now, let's consider our question: Could Lilly turn this into a multi-decade millionaire-maker opportunity? It's very possible. Analysts expect the obesity drug market to reach nearly $100 billion by the end of the decade – and to continue to grow beyond that point.

Why Eli Lilly is a leader

Lilly has secured its leadership in the market thanks to the solid efficacy of its products -- for example, Zebpound beat the performance of Wegovy in a head-to-head trial. And the potential approval of orforglipron -- easier to take than oral Wegovy because it doesn't involve dietary restrictions -- could generate additional growth. On top of this, this top pharma player has a strong pipeline with other promising products such as phase 3 candidate retatrutide.

Though other companies, from Pfizer to Viking Therapeutics, aim to enter the market in the coming years, Lilly's lead and brand strength should keep revenue climbing well into the future -- and this could power more gains for the stock. I wouldn't expect Lilly, alone, to make you a millionaire, but as part of a diversified portfolio, this pharma stock could help you reach that goal.

Should you buy stock in Eli Lilly right now?

Before you buy stock in Eli Lilly, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $443,299!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,136,601!*

Now, it’s worth noting Stock Advisor’s total average return is 914% — a market-crushing outperformance compared to 195% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of February 10, 2026.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy.

Original Article on Source

Source: “AOL Money”